Safety and Efficacy of Prophylactic Defibrotide in Patients With Sickle Cell Disease Following Myeloablative Conditioning and Haploidentical Stem Cell Transplantation

Trial Profile

Safety and Efficacy of Prophylactic Defibrotide in Patients With Sickle Cell Disease Following Myeloablative Conditioning and Haploidentical Stem Cell Transplantation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Defibrotide (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 05 May 2017 Status changed from not yet recruiting to recruiting.
    • 20 Sep 2016 Planned initiation date changed from 1 Feb 2016 to 1 Nov 2016.
    • 18 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top